Prophylaxis News and Research

RSS

Study explores links between antiretroviral prophylaxis, cleft lip and palate

HIV-positive mothers have been able to guard against transmitting the disease to their babies by taking antiretroviral drugs during pregnancy. Although the drugs prevent children from being born with HIV, they could cause birth defects, such as cleft lip and palate. A new study explores any links between antiretroviral prophylaxis and cleft lip and palate.

27 Jan 2012

IHS experts develop new guidelines for migraine clinical trials

Experts from the International Headache Society (IHS) have developed new recommendations for conduct of acute and preventive migraine clinical trials. The third edition of Migraine Clinical Trials Guidelines is now available in the IHS journal Cephalalgia, which is published by SAGE.

25 Jan 2012

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

Study confirms safety and effectiveness of rAHF-PFM in managing hemophilia A

A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.

10 Jan 2012

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

7 Jan 2012

Baxter commences BAX 855 Phase I trial in hemophilia A

Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.

From Baxter International Inc. 5 Jan 2012

Veloxis commences LCP-Tacro Phase IIIb study in kidney transplant patients

Veloxis Pharmaceuticals A/S today announced dosing of the first patient in the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) Phase IIIb study of LCP-Tacro in kidney transplant recipients experiencing drug-induced tremors.

4 Jan 2012

New gel could nip Lyme borreliosis infection in the bud

They come out in the spring, and each year they spread further - the ticks. Thirty percent of them transmit borrelia pathogens, the causative agent of Lyme borreliosis that can damage joints and organs.

19 Dec 2011

Baxter receives FDA approval for ADVATE to prevent hemophilia A

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.

From Baxter International Inc. 17 Dec 2011

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe.

17 Dec 2011

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.

9 Dec 2011

Global plan of action needed to end AIDS

After "President Obama threw the full weight of the U.S. government behind a vision" to end the AIDS epidemic in a World AIDS Day speech, "[n]ow the question is: How will we achieve this goal? What are the priority actions to take today, tomorrow, and years from now?" Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, writes in the Huffington Post's "Impact" blog.

8 Dec 2011

PrEP shows promise against HIV infection

A new weapon has emerged to prevent HIV infection. Called pre-exposure prophylaxis, or PrEP, it is a strategy of providing medications to at-risk people before they are exposed to the virus. Having shown great promise in recent phase 3 clinical trials, PrEP may soon be rolled out for public use.

8 Dec 2011

Researchers reveal ambivalent role of CXCL12/CXCR4 molecule in myocardial infarction

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

1 Dec 2011

Duplex ultrasound screening can detect high rate of LDVT's in critically ill trauma patients

A study published in the September 2011 issue of the Journal of Vascular Surgery®, the official publication of the Society for Vascular Surgery®, reports that a high rate of lower deep vein thromboses (LDVT's) in critically ill trauma cases can be detected through duplex ultrasound screening (DUS).

1 Dec 2011

VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa

VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - has stopped testing the gel.

29 Nov 2011